(CYTK) 4.86: Company published ongoing I / II stage Ispinesib; clinical trial data, the first stage was found that the best response rate was three patients functional damage reduced by 30% or more in diameter, where a tumor appeared local reactions, three patients after four months or longer periods in stable condition. The most common side effects were neutropenia syndrome, accounting for 85%.
Cytokinetics Post Ispinesib; clinical trial data
ReplyDelete(CYTK) 4.86: Company published ongoing I / II stage Ispinesib; clinical trial data, the first stage was found that the best response rate was three patients functional damage reduced by 30% or more in diameter, where a tumor appeared local reactions, three patients after four months or longer periods in stable condition. The most common side effects were neutropenia syndrome, accounting for 85%.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
VX-745
TAK-715
SB 239063
SD-06
Vinorelbine
LY2228820
PD0325901
Trametinib
GSK1120212 DMSO solvate
PD98059